In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate ...

The molecular glue degrader medicines furthest along in development are potential cancer treatments, but Monte Rosa Therapeutics is also researching how this therapeutic modality can treat ...

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ...

BOSTON, July 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ...

Shares of clinical-stage biotech Monte Rosa Therapeutics GLUE rose 44% on Monday after announcing that it had entered into a collaboration deal with pharma giant Novartis NVS to develop novel ...

Monte Rosa Therapeutics appointed Dr. Eric A. Hughes to its Board, enhancing R&D leadership for its molecular glue degrader pipeline. Monte Rosa Therapeutics, Inc. has announced the appointment of Dr.

Second agreement signed with Novartis to develop novel degraders for immune-mediated diseases, providing upfront payment of $120 million plus option maintenance payments, and eligibility for option ...

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, ...

Phase 1 study of NEK7-directed molecular glue degrader (MGD) MRT-8102 underway, to investigate a potential novel therapeutic approach for treating inflammatory diseases driven by the NLRP3 ...